Dietary potassium citrate does not harm the pcy mouse

Area of Science:

• Nephrology
• Genetics
• Pharmacology

Background:

• Inherited kidney diseases causing multiple cysts often lead to kidney failure.
• Current therapies lack definitive treatments to slow cystic kidney disease progression.
• Animal models are crucial for investigating potential therapeutic interventions.

Purpose of the Study:

• To evaluate the effect of potassium citrate supplementation in feed on renal cystic disease progression in pcy mice.
• To determine if citrate treatment, previously shown to benefit some models, adversely affects the pcy mouse model of nephronophthisis (NPHP3).

Main Methods:

• Male homozygous pcy mice were administered either regular feed or feed supplemented with 6% potassium citrate.
• Mice had ad libitum access to water and treatment began at 3 weeks of age.
• Survival rates of treated and untreated groups were compared to assess disease progression.

Main Results:

• Ingesting potassium citrate via feed did not significantly alter the survival curves of pcy mice.
• The progression of renal cystic disease in the pcy mouse model was not affected by dietary potassium citrate.
• This indicates citrate treatment is not detrimental to this specific model of cystic kidney disease.

Conclusions:

• Dietary potassium citrate does not impact renal cystic disease progression in the pcy mouse model, which resembles human nephronophthisis type 3 (NPHP3).
• Citrate treatment is not recommended for NPHP3 based on these findings.
• The lack of adverse effects removes a barrier for considering citrate therapy in autosomal-dominant polycystic kidney disease (ADPKD).